



(19) Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11) EP 0 458 367 B1

(12) EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention  
of the grant of the patent:  
17.10.2001 Bulletin 2001/42

(51) Int Cl.7: C12N 15/82, C12N 15/74,  
C12N 5/10

(21) Application number: 91109006.6

(22) Date of filing: 19.03.1987

(54) Anti-sense regulation of gene expression in plant cells

Anti-Sense-Regulierung von Genexpression in Pflanzenzellen

Réglage anti-sens d'expression de gènes dans les cellules végétales

(84) Designated Contracting States:  
AT BE CH DE ES FR GB GR IT LI LU NL SE

(56) References cited:  
EP-A- 0 159 779 EP-A- 0 223 399  
EP-A- 0 223 452 EP-A- 0 240 332  
EP-A- 0 271 988 WO-A-86/05516  
WO-A-88/01645

(30) Priority: 28.03.1986 US 845676  
17.10.1986 US 920574

(43) Date of publication of application:  
27.11.1991 Bulletin 1991/48

- NATURE, vol. 315, 13th June 1985, pages 601-603; J. COLEMAN et al.: "A novel immune system against bacteriophage infection using complementary RNA (microRNA)"
- BIO/TECHNOLOGY, June 1984, pages 520-527, Ciba-Geigy Corp., US; G. HELMER et al.: "A new chimeric gene as a marker for plant transformation: the expression of Escherichia Coli beta-galactosidase in sunflower and tobacco cells"
- PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE USA, vol. 83, no. 15, August 1986, pages 5372-5376, Washington, US; J.R. ECKER et al.: "Inhibition of gene expression in plant cells by expression of antisense RNA"
- J. CELL BIOCHEM., vol. 0, no. 10, part C, 1986, page 41, no J108; L.S. LOESCH-FRIES et al.: "Cloning of alfalfa mosaic virus coat protein gene and anti-sense RNA into a binary vector and their expression in transformed tobacco tissue"
- SCIENCE, vol. 229, 26th July 1985, pages 345-352; J.G. IZANT et al.: "Constitutive and conditional suppression of exogenous and endogenous genes by anti-sense RNA"

(62) Document number(s) of the earlier application(s) in  
accordance with Art. 76 EPC:  
87302367.5 / 0 240 208

(73) Proprietor: Calgene LLC  
Davis, California 95616 (US)

(72) Inventors:

- Shewmaker, Christine K.  
Woodland, California 95695 (US)
- Kridl, Jean C.  
Davis, California 95616 (US)
- Hiatt, William R.  
Davis, California 95616 (US)
- Knauf, Vic  
Davis, California 95616 (US)

(74) Representative: Armitage, Ian Michael et al  
MEWBURN ELLIS  
York House  
23 Kingsway  
London WC2B 6HP (GB)

EP 0 458 367 B1

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

**Description**

[0001] The modification of plants by genetic engineering has lagged behind the understanding and utilization of the molecular biology of unicellular organisms and mammalian cells. Techniques that have proven effective for stable transformation of unicellular microorganisms or mammalian cells with foreign DNA have not found useful analogy with plant cells. Therefore, despite the many achievements involved with unicellular microorganisms and mammalian cells, the number of achievements with plant cells has been substantially fewer and the experience with the other types of organisms has not been readily translatable into successful practices with plant cells.

[0002] In many situations it will be desirable to modify an existing trait of a plant cell, rather than introduce a new trait. Thus, one may wish to modify the activity of a particular enzyme, provide for the preferential expression of one allele as compared to another, one isozyme as compared to another, or the like. In many instances one may only wish to reduce the amount of expression of a structural gene, rather than inhibit expression entirely. It is therefore of interest to develop techniques which will allow for directed modification of the phenotype of particular plant cells, plant tissues or plants.

[0003] Crowley et al. *Cell* (1985) 43:633-641, describe the use of an anti-sense construct of the discoidin gene transfected into *Dictyostelium* to repress expression of endogenous discoidin genes. See also references cited therein. Anti-sense regulation has also been described by Rosenberg et al. *Nature* (1985) 313:703-706; Preiss et al. *Nature* (1985) 313:27-32; Melton, *Proc. Natl. Acad. Sci. USA* (1985) 82:144-148; Izant and Weintraub, *Science* (1985) 229: 345-352; and Kim and Wold, *Cell* (1985) 42:129-138. See also, Izant and Weintraub *Cell* (1984) 36:1007-1015; Pestka et al. *Proc. Natl. Acad. Sci. USA* (1984) 81:7525-7528; Mizuno et al. *Ibid* (1984) 81:1966-1970; Coleman et al. *Cell* (1984) 37:683-691; Travers, *Nature* (1984) 311:410 and Weintraub et al. *Trends in Genetics* (1985) 1:22-25. McGarry and Lindquist, *Proc. Natl. Acad. Sci. USA* (1986) 83:399-403, report the inhibition of heat shock protein synthesis by heat inducible anti-sense RNA.

**SUMMARY OF THE INVENTION**

[0004] The present Invention provides a method for regulating the expression of a gene in a plant cell which comprises:

30 integrating into said plant cell genome a construct comprising a promoter functional in said plant cell, a dsDNA sequence having the transcribed strand complementary to RNA endogenous in said cell and a termination region functional in said cell;  
growing said plant cell containing said integrated construct, whereby said complementary strand is transcribed and modulates the function of said endogenous RNA in said cell, provided:

35 (i) that the gene is not a plant parasite gene; and  
(ii) that said dsDNA sequence is not a polygalacturonase (PG) DNA sequence as found in the EcoRI insert of plasmid pCGN1401 (ATCC67227), or as obtainable by the use of said insert DNA as a hybridization probe.  
40 The Invention further provides a DNA construct comprising a transcriptional initiation region functional in a plant cell; a dsDNA sequence having as the transcribed strand a sequence complementary to an RNA sequence endogenous to a plant cell, and a transcriptional termination region, provided:  
(i) that said RNA sequence is not a plant parasite RNA sequence;

45 (ii) is not a zein sequence; and  
(iii) is not a polygalacturonase (PG) DNA sequence as found in the EcoRI insert of plasmid pCGN1401 (ATCC67227), or as obtainable by the use of said insert DNA as a hybridization probe.

**BRIEF DESCRIPTION OF THE DRAWINGS****[0005]**

55 Fig. 1 indicates the EcoRI-BamHI fragment from pCGN 1401. This fragment corresponds to the 5'-portion of P1 including the region encoding the N-terminus of the mature polygalacturonase protein. The underlined amino acids are predicted from the DNA sequence and agree with the amino acid sequence determined by chemical sequencing from purified polygalacturonase; and

Fig. 2 is a flow chart of the various plasmids used in the construction of the binary vector pCGN783.

#### DESCRIPTION OF THE SPECIFIC EMBODIMENTS

5 [0006] Methods and compositions are provided for modulating RNA utilization, particularly modulation of a phenotypic property of a plant host cell. The compositions involve transcription constructs having transcriptional initiation and termination regions separated by a sequence which is complementary to a sequence present on RNA, particularly messenger RNA, endogenous to the host. By this means, various processes endogenous to the plant host cell may be modulated, so that the production of individual proteins may be reduced, multi-enzyme processes modulated, particular metabolic paths modulated or inhibited in preference to one or more other metabolic paths, production of non-proteinaceous products reduced, cell differentiation modified, and the like.

10 [0007] The sequence complementary to a sequence of the messenger RNA will usually be at least about 15 nucleotides, more usually at least about 20 nucleotides, preferably about 30 nucleotides, and more preferably about 50 nucleotides, and may be 100 nucleotides or more, usually being fewer than about 5000 nucleotides, more usually being fewer than 2000 nucleotides, and preferably being fewer than 1000 nucleotides. The sequence may be complementary to any sequence of the messenger RNA, that is, it may be proximal to the 5'-terminus or capping site, downstream from the capping site, between the capping site and the initiation codon and may cover all or only a portion of the non-coding region, may bridge the non-coding and coding region, be complementary to all or part of the coding region, complementary to the 3'-terminus of the coding region, or complementary to the 3'-untranslated region of the mRNA.

15 [0008] In referring to Messenger RNA, the Messenger RNA may be processed or unprocessed, that is including introns. Thus, the non-coding region may include the 5' or 3' non-coding flanking regions and the introns.

20 [0009] The particular site(s) to which the anti-sense sequence binds and the length of the anti-sense sequence will vary depending upon the degree of inhibition desired, the uniqueness of the sequence, the stability of the anti-sense sequence, or the like. Therefore, to some degree, these factors will be determined empirically based on the experience observed with a particular anti-sense sequence.

25 [0010] The sequence may be a single sequence or a repetitive sequence having two or more repetitive sequences in tandem, where the single sequence may bind to a plurality of messenger RNAs. In some instances, rather than providing for homoduplexing, hetero-duplexing may be employed, where the same sequence may provide for inhibition of a plurality of messenger RNAs by having regions complementary to different messenger RNAs.

30 [0011] The anti-sense sequence may be complementary to a unique sequence or a repeated sequence, so as to enhance the probability of binding. Thus, the anti-sense sequence may be involved with the binding of a unique sequence, a single unit of a repetitive sequence or of a plurality of units of a repetitive sequence. The anti-sense sequence may result in the modulation of expression of a single gene or a plurality of genes.

35 [0012] The transcriptional construct will be comprised of, in the direction of transcription, a transcriptional initiation region, the sequence coding for the anti-sense RNA on the sense strand, and a transcriptional termination region.

40 [0013] The transcriptional initiation region may provide for constitutive expression or regulated expression. A large number of promoters are available which are functional in plants. These promoters may be obtained from Ti- or Ri-plasmids, from plant cells, plant viruses or other hosts where the promoters are found to be functional in plants. Illustrative promoters include the octopine synthetase promoter, the nopaline synthetase promoter, the manopine synthetase promoter, etc., as illustrative of promoters of bacterial origin functional in plants. Viral promoters include the cauliflower mosaic virus full length (35S) and region VI promoters, etc. Endogenous plant promoters include the ribulose-1,6-biphosphate (RUBP) carboxylase small subunit (ssu), the  $\beta$ -conglycinin promoter, the phaseolin promoter, the ADH promoter, heat-shock promoters, tissue specific promoters, e.g., promoters associated with fruit ripening, etc.

45 [0014] The transcriptional initiation region may be a naturally-occurring region, a RNA polymerase binding region freed of the regulatory region, or a combination of an RNA polymerase binding region from one gene and regulatory region from a different gene. The regulatory region may be responsive to a physical stimulus, such as heat, with heat shock genes, light, as with the RUBP carboxylase SSU, or the like. Alternatively, the regulatory region may be sensitive to differentiation signals, such as the  $\beta$ -conglycinin gene, the phaseolin gene, or the like. A third type of regulatory region is responsive to metabolites. The time and level of expression of the anti-sense RNA can have a definite effect on the phenotype produced. Thus the promoters chosen will determine the effect of the anti-sense RNA.

50 [0015] Any convenient termination region may be employed, conveniently the termination region of the RNA polymerase binding region, or a different termination region. Various termination regions are available and the choice is primarily one of convenience, where prior constructions or DNA sequences may be available. Conveniently, the opine termination regions may be employed, or termination regions from endogenous genes, such as the genes which have been described previously.

55 [0016] The various fragments may be joined by linkers, adapters, or the like, or directly where convenient restriction sites are available. The DNA sequences, particularly bound to a replication system, may be joined stepwise, where markers present on the replication system may be employed for selection.

[0017] The constructions of the subject invention may be introduced into the host cell in a variety of ways. Of particular interest is the use of *A. tumefaciens*, with protoplasts, injured leaves, or other explant tissues. Other techniques which may find use include electroporation with protoplasts, liposome fusion, microinjection, or the like. The particular method for transforming the plant cells is not critical to this invention.

[0018] Any plant may be employed in accordance with this invention, including angiosperms, gymnosperms, monocotyledons, and dicotyledons. Plants of interest include cereals such as wheat, barley, maize, triticale, etc.; fruits, such as apricots, oranges, grape-fruits, apples, pears, avocados, etc.; nuts, such as walnuts, almonds, filberts, pecans, etc.; vegetables, such as carrots, lettuce, tomatoes, celery, turnips, potatoes, broccoli, asparagus, etc.; woody species, such as poplar, pine, sequoia, cedar, oak, etc; ornamental flowers; or other cash crops, such as tobacco, jojoba, rapeseed, Cuphea, soybeans, sunflower, sugar beet, safflower, etc. For each species, there will generally be different genes to modulate, so as to change the phenotype of the host.

[0019] After the cells have been transformed, the cells will be regenerated into plants. Various techniques exist for regenerating plants from cells. Calli can be developed from the cells and the calli induced to form shoots which may then be transferred to an appropriate nutrient medium in soil to regenerate the plant. The plants will then grow and, as appropriate, may be crossed with other plants so as to establish the stability of the change in phenotype over a number of generations. Other techniques may be employed for regenerating the plants without pollination or fertilization. Because those plant genotypes that can be regenerated from culture may not be directly applicable as crop varieties, the transformed plant may be crossed with alternate untransformed germplasm in order to transfer the trait to appropriate breeding lines.

[0020] A wide variety of modifications may be made in numerous types of plants. These modifications may include varying the fatty acid distribution of a fatty acid source, such as rapeseed, Cuphea or jojoba, delaying the ripening in fruits and vegetables, changing the organoleptic, storage, packaging, picking and/or processing properties of fruits and vegetables, delaying the flowering or senescing of cut flowers for bouquets, reducing the amount of one or more substances in the plant, such as caffeine, theophylline, nicotine, altering flower color.

[0021] For changing the fatty acid distribution, target species could be coconut and palm trees, Cuphea species, rapeseed, or the like. The target genes of particular interest could be acetyl transacylase, acyl carrier protein, thioesterase, etc.

[0022] For varying the amount of nicotine, a target species could be tobacco. The target genes could be N-methyl-putrescine oxidase or putrescine N-methyl transferase.

[0023] For delaying the ripening in fruits, the target species could be tomato or avocado. The target genes could be polygalacturonase or cellulase.

[0024] For varying the amount of caffeine, the target species could be coffee (*Coffea arabica*). The target gene could be 7-methylxanthine, 3-methyl transferase.

[0025] For varying the amount of theophylline, the species could be tea (*Camellia sinensis*). The target gene could be 1-methylxanthine 3-methyl transferase.

[0026] For altering flower color the targets could be petunia, roses, carnations, or chrysanthemums, etc. The target genes could be chalcone synthase, phenylalanine ammonia lyase, or dehydrokaempferol (flavone) hydroxylases, etc.

[0027] For altering lignin content, the targets could be loblolly pine, Douglas fir, poplar, etc. The target genes could be cinnamoyl-CoA:NADPH reductase or cinnamoyl alcohol dehydrogenase, etc.

[0028] In general, reducing the activity of one enzyme at a branch point in a metabolic pathway could allow alteration of the ratios of the products formed.

[0029] The transcription construct will usually be joined to a replication system, particularly a bacterial replication system, for manipulation and cloning during its construction. The replication system can be any convenient replication system, particularly one that is functional in *E. coli*, and one or more markers may be present for detecting transformed bacteria.

[0030] Where *A. tumefaciens* or *A. rhizogenes* is employed for transferring the DNA, the construction will also be joined to at least one T-DNA border. Thus, the construction will include one T-DNA border, particularly the right T-DNA border, or may be sandwiched between the left and right T-DNA borders.

[0031] Various techniques exist for transferring the construct employing the Ti- or Ri-plasmid as the means for the transfer. These techniques include providing for a plasmid which is capable of replication in *Agrobacterium*, where the construct in T-DNA becomes integrated into the Ti- or Ri-plasmid by recombination. Alternatively, binary vectors may be employed, where the Ti- or Ri-plasmid in the *Agrobacterium* may or may not have a T-DNA region homologous with the T-DNA of the construct. In either event, so long as the *vir* genes are present on the endogenous plasmid, the T-DNA can be transferred successfully to the plant.

[0032] By having a marker as part of the expression construct, particularly antibiotic resistance, such as kanamycin resistance, hygromycin resistance, gentamycin resistance, bleomycin resistance, etc., one can select for those plant cells which have retained the construct in functional form. Where binary vectors are being employed and where the T-DNA in the Ti- or Ri-plasmid of the *Agrobacterium* retains the oncogenes, one will select for morphologically normal

cells, which lack oncogenic expression.

[0033] Where electroporation or microinjection is employed, there need be no concern about gall formation and one expects that the morphology of the resulting plants would be normal, except for the modified phenotype.

5 [0034] An example of the use of an anti-sense strand is the regulated modulation of the expression of polygalacturonase (PG) in tomatoes. The ability to reduce the production of polygalacturonase could have a positive effect on the solids content of the tomato plant and improve tomato processing.

[0035] To control polygalacturonase expression in tomato fruit a transcription construct is prepared having the anti-sense strand of the polygalacturonase gene transcribed. The entire gene including flanking regions need not be employed, conveniently cDNA or a fragment thereof may be employed. The fragment will be from about 100 to 2000nt, more usually from 150 to 1000nt.

10 [0036] The transcription initiation regulatory region is desirably inducible, rather than constitutive, particularly being active at the time of fruit breaking (shortly prior to ripening). For this purpose the polygalacturonase gene transcriptional initiation region may be employed or a transcriptional initiation region of another gene associated with the development of fruit during ripening.

15 [0037] The manner of construction of the transcription cassette need not be repeated here. Once the construct has been prepared, it is introduced into tomato plant cells in accordance with conventional ways, and plants regenerated from the cells.

[0038] The following examples are offered by way of illustration and not by way of limitation.

20 **EXPERIMENTAL**

**Example 1:**

**AroA Anti-Sense**

25 **Materials and Methods**

[0039] T4 ligase was from ProMega Biotech. Restriction enzymes, Klenow polymerase fragment, and Bal31 were from Bethesda Research Laboratories (BRL).

30 **Construction of the octopine cassette, pCGN451.**

[0040] The ocs5'-ocs3' cassette, was inserted into a derivative of pUC8 (Vieira and Messing, Gene (1982) 19: 259-268), where a XbaI linker (CCTCGAGG) was inserted at the HincII site and the EcoRI site removed by filling in with the Klenow fragment of DNA polymerase. The octopine synthetase cassette was prepared by linking the XbaI (15208)-BamHI (13774) fragment from the octopine Ti-plasmid pTiA6 (Currier and Nester (1976) J. Bact. 126:157-165; Thomashow et al. Cell (1980) 19:729-739) containing the T-DNA border to the cut-down BamHI (13774) to EcoRI (linker) fragment (the numbering is by Barker, et al. Plant Mol. Biol. (1983) 2:335-350, for the closely related Ti-plasmid pTi15955). The cut-down BamHI-EcoRI fragment was obtained by digesting an EcoRI (13362) to BamHI (13774) subclone of the T-region of pTiA6 with XbaI (13512), followed by resection with Bal31 exonuclease. EcoRI linkers (GGAAT-TCC) were added and EcoRI to BamHI fragments of approximately 130bp gel purified, cloned into M13mp9 and sequenced. A clone in which the EcoRI linker was inserted at 13642 between the transcription initiation point and the translation initiation codon was identified by comparison with the sequence of de Greve et al. J. Mol. Appl. Genet. (1982) 1:499-512.

45 [0041] The EcoRI cleavage site was at position 13539, downstream from the mRNA start site. The SmaI site at 11207 was converted to a XbaI site using oligonucleotide linkers (CCTCGAGG) and the 3' end of the octopine gene from the EcoRI (12823) to the converted XbaI site added to the cassette. The resulting expression cassette having the octopine synthetase 5'-region (15208-13639) and 3'-region (12823-11207) was then inserted into the XbaI site of the modified pUC8 to provide pCGN451.

50 **Construction of the aroA Sense/Anti-Sense Binary Plasmid.**

[0042] pPMG38 (Comai et al. Nature (1985) 317:741-744) was digested with BamHI to provide a fragment containing the aroA gene (nucleotides 1377-2704; Stalker et al. J. Biol. Chem. (1985) 260:4724-4728), which was inserted into the BamHI site of the mas5'-ocs3' cassette, pCGN46 (Comai et al. Nature (1985) 317:741-744) in the anti-sense (minus orientation) with respect to the mas promoter to provide pCGN964b.

55 [0043] The same aroA gene as described above, as an EcoRI fragment from pPMG38, was inserted into pCGN451 in the octopine cassette, after digestion of pCGN451 with EcoRI resulting in plasmid pPMG45 (ocs-aroA).

[0044] pCGN525 resulted from combining the large HindIII-BamHI fragment of pACY184 (Chang and Cohen, J. Bact. (1978) 134:1141-1156) with the HindIII-BamHI fragment of the bacterial kanamycin resistance gene from Tn5 (Jorgensen et al. Molec. Gen. Genet. (1979) 177:65-72). The Xhol fragment of pPMG45 was inserted into the Sall site of pCGN525 to provide pCGN963. The HindIII site of pCGN963 was replaced with a Xhol linker (CCTCGAGG) and the Xhol fragment from pCGN964 containing the mas-anti-sense aroA construct was inserted into this new Xhol site. This plasmid, containing both the sense and anti-sense aroA genes, is pCGN965.

[0045] pCGN978, a binary vector, was constructed by ligating pCGN965 and pRK290 (Ditta et al. Proc. Natl. Acad. Sci. USA (1980) 77:7347-7351) after digestion with BgIII.

10 Construction of pPMG54, An aroA Sense Plasmid.

[0046] The aroA gene, as a Xhol fragment, from pPMG45 was inserted into pCGN517 digested with Sall to provide pPMG54. pCGN517 is prepared from pHC79 (Hohn and Collins, Gene (1980) 11:291-298) with the kanamycin resistance gene of Tn903 from pUC5K (Vieira and Messing, Gene (1982) 19:259-268) inserted at the PstI site.

15 Mating to Agrobacterium tumefaciens and Gall Formation.

[0047] pCGN978 and pPMG54 were each plate mated with *A. tumefaciens* strain K12 (strain K12 was generated by transforming pTiA6 into strain A114 (NT1); (Scialy et al. Plasmid (1978) 1:238-253) and pRK2073 (Leong et al. J. Biol. Chem. (1982) 257:8724-8730). The plate-mating protocol is described by Comai et al. Plasmid (1983) 10:21-30. *Agrobacterium* carrying pCGN978 was selected on AB plates (Chilton et al. Proc. Natl. Acad. Sci. USA (1974) 71: 3672-3676) plus 200 $\mu$ g/ml streptomycin and 50 $\mu$ g/ml kanamycin and the presence of pCGN978 confirmed by Southern analysis. Recombinants with pPMG54 integrated into the T-DNA of K12 were selected on AB plates plus 100 $\mu$ g/ml kanamycin and confirmed by Southern analysis.

20 [0048] Galls were induced on 3- to 4-month-old Kalanchoe plants by wounding leaves with toothpicks dipped in a solution of pCGN978xK12 and pPMB54xK12 (about 10<sup>9</sup> bacteria/ml in MG/L broth (Garfinkel and Nester, J. Bacteriol. (1980) 194:732-743). Gall material was harvested from four plants for each construct after four weeks and frozen at -70°C until use. The gall material was randomized for each construct and analyzed for aroA protein by Western analysis.

25 [0049] The Western analysis was performed as follows: 2.3g of pPMB54xK12 and 3.0g of pCGN978xK12 gall tissue were ground in liquid nitrogen. 0.3g/g tissue of polyvinylpyrrolidone was added. The tissue was suspended in 1.5ml/g tissue of 0.1M sodium citrate, pH 5.6, 10mM EDTA, 0.15M NaCl, 0.05% Nonidet P-40, 25mg/ml bovine serum albumin (BSA), 1mM dithiothreitol, 1mM phenylmethylsulfonyl flouride (PMSF), 10 $\mu$ m leupeptin (Sigma) and 10mM thiourea. The homogenate was centrifuged at 15,000g for 15min at 4°C. 25 $\mu$ l of antiserum, prepared by injecting purified 3-enolpyruvylshikimate phosphate (EPSP) synthase into rabbits and 125 $\mu$ l 10% (w/v) suspension of *S. aureus* (Calbiochem) were added to each supernatant and incubated with agitation for 1h at room temperature.

30 [0050] Samples were then centrifuged (5000xg, 5min) and the pellet washed twice with 50mM Tris, pH 7.5 1mM EDTA, 0.5M NaCl and 0.05% Nonidet P-40. The resulting pellets were suspended in 100 $\mu$ l 0.125M Tris, pH 6.8, 4% SDS, 20% glycerol and 10% 2-mercaptoethanol and heated for 2min at 90°C. The entire sample was then electrophoresed on a 10% acrylamide gel. The resolved peptides were transferred to nitrocellulose (BA85, Schleicher and Schuell) as described by Burnette Anal. Biochem. (1981) 112:195-203) at 100V for 3hr in a Hoefer TE42 transfer unit. Nitrocellulose filters were then incubated in BLOTTO (20mM Tris, pH 7.5, 5% dehydrated skim milk, 0.5M NaCl, 0.1% anti-foam A, 10mM Na Azide) for 1hr at room temperature, followed by an overnight incubation at 4°C in BLOTTO containing a 1:50 dilution of anti-EPSP synthase serum. Filters were washed for 10min in 20mM Tris, pH 7.5, 150mM NaCl, for 20min in the same buffer containing 0.05% Tween-20 and for another 10min in buffer without detergent. BLOTTO containing 10<sup>6</sup>cpm/ml of <sup>125</sup>I-labeled protein A (9 $\mu$ Ci/mg; NEN) was then added to filters and incubated at room temperature for 2hr. The filters were washed overnight in 50mM Tris, pH 7.5, 1M NaCl and 0.4% lauryl sarcosine and then washed for 3hr at room temperature in 50mM Tris, pH 7.5, 5mM EDTA, 150mM NaCl, 0.5% Triton X-100, and 0.1% SDS. After rinsing and drying, filters were exposed to Kodak XAR X-ray film at -70°C using a DuPont Lightning Plus intensifying screen.

45 [0051] The pCGN978 containing gall showed only 10-20% of the activity of the control pPMG54 galls. Earlier comparisons of the expression of aroA in the binary system versus the integrated system showed that the binary system is only 70-80% as efficient as the integrated system. Therefore, an overall decrease in aroA activity of 60% is observed where the anti-sense construct is also present.

50 Experimental for Electroporation Experiments Plasmid Contructions.

[0052] The anti-sense 5'mas-aroA-3'ocs construct, pCGN964b, was constructed as described above. The sense 5'mas-aroA-3'ocs construct, pCGN964a, was obtained from the same ligation, with the sense orientation being select-

ed.

Plant material.

5 [0053] Protoplast donor plants of Nicotiana tabacum cv. Xanthi were grown in glass jars under aseptic conditions as described elsewhere (Faccioli and Pilet, 1979). Apical shoots were placed in 100ml of agar medium (Murasahige and Skoog (MS) medium) containing 0.7% Gibco Phytagar, 30g/l sucrose, 1.0mg/l IAA and 0.15mg/l Kinetin, adjusted to pH 5.55 prior to autoclaving). The cultures were kept at 23±2°C under a 12hr dark/light regime.

10 [0054] The following steps were performed under aseptic conditions with sterile solutions.

10 [0055] Young leaves were removed from 4-5 week old plants during the dark portion of the cycle. The main veins were discarded, and the remaining leaf tissue was cut once longitudinally. These leaf sections were infiltrated (to 200 millitorr) with a 6% sorbitol solution containing 0.4% pectinase (Pectolyase Y-23, Seishin Pharmaceutical Co. Ltd., Japan) and 0.6% cellulase (Onozuka RS, Yakult Pharmaceutical Industry Co. Ltd., Japan). After 2-3hr incubation, the macerate was gently pipetted to release protoplasts and passed through a 52μ nylon filter. The protoplasts were pelleted by centrifugation at 50xg, and washed twice with 7% sorbitol solution. Protoplast density was determined by use of a hemacytometer (using a 1mm, 9 square grid, the average of the squares counted multiplied by 10<sup>4</sup> yields an estimate of the total number of protoplasts per ml). Based on the calculated density, protoplasts were suspended at a final density of 2.2-3.0 million per ml in buffer (buffer containing: 10mM Hepes pH 7.1, 140mM NaCl, 5mM CaCl<sub>2</sub> and 6% sorbitol).

20

Electroporation.

25 [0056] Protoplasts suspended in buffer were divided into 1ml aliquots. To each aliquot 1mg of carrier DNA (in the form of herring sperm DNA) was added. Following the addition of carrier DNA, plasmid DNA was added in the desired concentrations. The protoplast/DNA mixture was incubated for 5min prior to electroporation and subsequently transferred to 1ml aluminum foil lined plastic cuvettes for electroporation. The electroporation pulse was delivered by a 1250μF capacitor charged to 150 volts. The pulse duration was measured through the buffer solution, devoid of protoplasts, and found to be 40msec. Following electroporation the protoplasts were incubated for 10min at room temperature in the cuvette, and subsequently transferred to Petri plates, diluted with 10ml of protoplast culture media (MS salts containing 0.6mg/l NAA, 0.2mg/l 2,4-D, 0.8mg/l Kinetin, 5.5% sorbitol and 30g/l sucrose) and cultured at 23±2°C in complete darkness. After 48-50hr the protoplasts were harvested by gentle centrifugation (50xg for 6min), the supernatant removed and protoplasts frozen in liquid nitrogen and stored at -70°C. At a later date the frozen protoplast pellet was suspended in 1ml of extraction buffer for Western analysis (containing: 0.1M Na Citrate, 10mM EDTA, 150mM NaCl, 0.05% Nonidet, 25mg/ml BSA, 1mM PMSF, 10mM DTT, 10mM thiourea, 10μM leupeptin). 0.05g/ml polyvinylpyrrolidone (PolyClarAT, BDH) was added and the mixture ground for 30sec in a Polytron homogenizer. The supernatant was collected and Western analysis performed as described above.

Experiments.

40 [0057] Experimental treatments utilized pCGN964a and pCGN964b (see section on Plasmid construction for details of each construct). In each experiment treatments containing both 964a and 964b were compared to treatments containing 964a or 964b alone:

45

50μ 964a	0μ 964b
50μ 964a	10μ 964b
50μ 964a	25μ 964b
50μ 964a	50μ 964b
50μ 964a	100μ 964b
0μ 964a	50μ 964b

50

In all cases the addition of the anti-sense DNA (964b) reduced the protein level detected by Western analysis (compared to levels obtained with 964a alone). The reduction in level averaged 50%. No protein was detected in 964b alone, as expected.

55

Example 2:Polygalacturonase Anti-sense Construct.5 Bacterial Strains.

[0058]

Table I.

Bacterial Strains			
	Escherichia Coli Designation	Phenotype	Origin/Reference
10	7118	$\Delta$ lac	<u>Vieira and Messing</u> <u>Gene (1982) 19:259-268</u>
15	Y1088	<u>hsdR</u> <u>hsdM</u> <sup>+</sup>	<u>Young and Davis</u> <u>PNAS USA (1983)</u> <u>80:1194-1198</u>
20	Y1090	$\Delta$ lon	
	C2110	polA	<u>Stalker et al.</u> <u>PNAS USA (1983)</u> <u>80:5500-5504</u>

25 Enzymes and Radioisotopes

[0059] All enzymes were obtained from commercial sources and used according to the manufacturer's suggestions. Radioisotopes were obtained from New England Nuclear.

30 Isolation of poly(A)+RNA

[0060] Ripe fruit of tomato cv. CaliGrande was harvested and frozen in liquid N<sub>2</sub>. Frozen tissue was ground in a mortar and pestle in liquid N<sub>2</sub>, and the resulting powder was extracted by homogenization with a Brinkman polytron in buffer described by Facciotti et al. Bio/Technology (1985) 3:241-246. Total RNA was prepared as described by Colbert et al. Proc. Natl. Acad. Sci. USA (1983) 80:2248-2252.

[0061] Polysaccharides were precipitated from total RNA preparations with 40mM sodium acetate and 0.5 vol ethanol (Mansson et al. (1985) Mol. Gen. Genet. (1985) 200:356-361). Poly(A)+RNA was isolated as described by Maniatis et al. (1982) Molecular Cloning: A Laboratory Manual, Cold Spring Harbor, New York.

40 Synthesis of cDNA

[0062] Synthesis of cDNA from poly(A)+RNA was performed as described by Gubler and Hoffman, Gene (1983) 25: 263-269 with the following modifications: The reaction mixture for synthesis of the first strand included 1mM dGTP, 1mM dATP, 1mM TTP, 0.5mM dCTP, 0.5 unit/ $\mu$ l RNasin (Promega), 4 $\mu$ g of tomato poly(A)+RNA, and 80-100 units of reverse transcriptase (Life Sciences). The reaction was stopped with 2 $\mu$ l of 500mM EDTA, then precipitated with 10 $\mu$ g tRNA, 1 vol 4M NH<sub>4</sub>OAc, and 2.5 vol of ethanol overnight on dry ice.

[0063] Second strand synthesis was performed from approximately 500ng of the first strand reaction product. Aliquots of the first and second strand reaction mixtures were radiolabeled separately with 20 $\mu$ Ci of 5'-[ $\alpha$ -<sup>32</sup>P] dCTP to monitor each reaction independently.

50 Cloning of Double-Stranded cDNA in  $\lambda$ gt11.

[0064] The double-stranded cDNA was EcoRI methylated as described by the manufacturer (New England Biolabs). After ethanol precipitation, the cDNA ends were blunted using 3 units of the Klenow fragment of DNA polymerase I (Bethesda Research Laboratories) the following conditions: 66mM Tris-HCl pH 7.5, 20mM MgCl<sub>2</sub>, 100mM dithiothreitol, 100 $\mu$ M dGTP, dATP, TTP, and dCTP at room temperature for 1 hr. The DNA was then ethanol precipitated. After blunting, 2 $\mu$ g of EcoRI phosphorylated linkers were added to the cDNA in 10 $\mu$ l of ligase buffer (50mM Tris, pH 7.5, 10mM MgCl<sub>2</sub>, 20mM dithiothreitol, 1mM ATP, and 5mg/ml bovine serum albumin). T<sub>4</sub> DNA ligase (1 Weiss unit, Weiss,

J. Biochem. (1968) 243:4543, Promega) was added and incubated for 6 hr at 15°C. An additional Weiss unit of T<sub>4</sub> DNA ligase in 10μl of ligase buffer was then added and incubated for 24 hr at 15-19°C. The reaction was phenol extracted, ethanol precipitated and digested with 100 units EcoRI (New England Biolabs) for 6-8 hrs, phenol extracted and ethanol precipitated. Excess linkers and cDNA fewer than 500 base pairs were removed by chromatography on Bio-gel A-50m (100-200 mesh) and the sized cDNA was ligated to EcoRI-cleaved λgt11 vector DNA (Stratagene) as described by Huynh et al. in DNA Cloning: A Practical Approach, ed. D.M. Glover, pp. 49-78, IRL Press, Oxford, England, 1985.

[0065] In vitro packaging reactions were performed with Giga-pack extracts (Stratagene) as described by the vendor. Initial test ligations and in vitro packaging were done using various dilutions of cDNA to empirically determine the optimal ratio of cDNA/vector for production of recombinant phage. The packaged λgt11 phage were plated on E. Coli Y1088 in the presence of Isopropyl-1-thio-β-D-galactoside (IPTG) and 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal) as described by Huynh et al. (1985), supra to determine the number of recombinants. Greater than 5x10<sup>6</sup> recombinants at a 90% insertion rate was obtained in λgt11.

15 Library Screening

[0066] Approximately 200,000 phage from an unamplified λgt11 library were screened at a density of 20,000 plaques-forming units per 9cm square plate using E. coli Y1090 as the host as described by Huynh et al. (1985), except that NZY media (per liter: 5g NaCl, 2g MgCl<sub>2</sub>, 10g NZamine type A (Sheffield Products), 5g yeast extract and 15g agar) was used. Plates were incubated and overlaid with nitrocellulose sheets containing IPTG as described by Huynh et al. (1985), supra. The nitrocellulose sheets were saturated with 0.5M Tris pH 8.0, 0.15M NaCl, 0.02% NaN<sub>3</sub>, 0.1% Triton X-100 and 5% non-fat dry milk, then incubated 30 min at room temperature with the same buffer containing anti-polygalacturonase2 antibody (see below) diluted 1:1000. Bound antibody was detected with an alkaline phosphatase-conjugated second antibody (Promega) as described by the vendor. Positive plaques were purified by successive plating and phage DNA was prepared as described (Maniatis et al. (1982)).

Subcloning and Sequencing of cDNA Insert P1

[0067] Phage DNA from positive plaque P1 was digested with EcoRI and the resulting fragment was subcloned in EcoRI-digested vector M13 Blue Scribe Minus (Stratagene) by in vitro ligation. Initial DNA sequencing was performed using single-stranded template from the Blue Scribe construct prepared as described by the manufacturer. All DNA sequencing was performed as described by Sanger et al., Proc. Natl. Acad. Sci. USA (1977) 74:5463 or Maxam and Gilbert, Methods Enzymol. (1980) 65:499-580. Overlapping sequences were obtained by subcloning purified BamHI-EcoRI, HinDIII-EcoRI, and BamHI-HinDIII fragments (Maniatis et al., supra) from the Blue Scribe construct into M13mp18 (Yanisch-Perron et al. Gene (1985) 53:103-119) and M13mp19 (Norrander et al. Gene (1983) 26:101-106).

Polygalacturonase Purification for Protein Sequencing

[0068] Total cell-wall bound proteins were prepared from ripe fruit of cv. CaliGrande as described by Crookes and Grierson, Plant Physiol. (1983) 72:1088-1093. The extract was dialyzed against 0.025M ethanolamine, pH 9.4, and applied to a 9 x 300mm column of chromatofocusing exchanger PBE 94 (Pharmacia) equilibrated with 0.025M ethanolamine, pH 9.4. Bound proteins were eluted with Polybuffer 96, pH 8.0 (Pharmacia). Fractions containing polygalacturonase were pooled and precipitated with ammonium sulphate (90% saturation) and further fractionated by chromatography over a hydroxyapatite (HAPT) HPLC column. Two ml volumes were layered onto the column and chromatographed at 1 ml/min using a linear gradient extending from 10mM to 350mM sodium phosphate, pH 6.8. Samples were monitored at A<sub>280</sub> and fractionated into 0.5ml volumes. Fractions collected from numerous runs which contained polygalacturonase were pooled and dialyzed against 6% acetic acid, then lyophilized.

50 Protein Sequencing

[0069] Polygalacturonase prepared as described above was sequenced intact with a Beckman 890 M Liquid Phase Amino Acid Sequencer. The following N-terminal sequence was obtained: Gly-Ile-Lys-Val-Ile-Asn.

Polygalacturonase Purification for Antibody Production

55 [0070] Tomato cell wall bound proteins were prepared from ripe fruit of cv. UC82B as described by Tucker and Grierson, Planta (1982) 155:64-67. The pellet from ammonium sulphate precipitation was dissolved in 150mM NaCl and then dialyzed overnight against the same buffer.

[0071] The protein solution was then fractionated on a TSK 3000/2000 HPLC sizing column using an isocratic gradient containing 10mM NaCl and 10mM Tris pH 7.2 at a flow rate of 0.5 ml/min.

[0072] TSK fractions containing polygalacturonase activity (Reisfeld et al. *Nature* (1962) 195:281-283) were pooled and further fractionated over an hydroxyapatite HPLC column using a linear gradient of 10mM-350mM sodium phosphate, pH 6.8 and a flow rate of 1 ml/min. The peak containing polygalacturonase activity was collected and used to inject rabbits for antibody production.

[0073] Polygalacturonase for booster injections was prepared by resolving the cell wall bound protein preparation on SDS polyacrylamide gels. The material precipitated with ammonium sulphate (see above) was electrophoresed on 3mm thick and 14mm wide gels containing 12.5% polyacrylamide (Laemmli, *Nature* (1970) 227:680-685) and proteins were visualized by staining with Coomassie Brilliant Blue R. The region corresponding to the polygalacturonase bands (approximately 40,000 - 43,000 daltons) was excised, frozen, and ground with liquid N<sub>2</sub>.

#### Antibody Preparation

[0074] One rabbit was given 4 injections of polygalacturonase (125 $\mu$ g injection) over a one month period. The same rabbit was then given a booster injection of polygalacturonase (approximately 150 $\mu$ g) recovered from SDS polyacrylamide gels. An identical booster injection was again given one week after the first. The animal was exsanguinated 2 weeks later as a source of serum.

[0075] Six ml of the crude serum were diluted with 6ml of 0.1M sodium phosphate, pH 7.0, and applied to a 6ml column of Protein A-Sepharose (Sigma). The column was washed with 80ml of 0.1M sodium phosphate, pH 7.0, and the IgG fraction was then eluted with 0.1M glycine, pH 3.0. Fractions with the highest A280 were pooled, dialyzed against 20mM sodium phosphate pH 7.6, 150mM NaCl and concentrated on an Amicon XM80 membrane. Glycerol was then added to a final concentration of 40%.

[0076] Affinity purified antiserum was prepared by incubating the IgG fraction with polygalacturonase linked to a Tresacryl (Pharamacia) affinity chromatography matrix as described by the vendor. Polygalacturonase purified for protein sequencing was linked to 4ml of Tresacryl resin as described by the manufacturer. Five ml of IgG prepared as described above was diluted to 50ml with 0.01M Tris pH 7.5, 150mM NaCl and 0.1% Tween-20 (TBST) and incubated with the resin overnight at 4°C. The resin was then washed with TBST and eluted with 0.2M glycine, pH 2.75. Fractions with A280 were pooled and dialyzed against 10mM Tris pH 8.0, 150mM NaCl. The final volume of purified antibody was 12ml representing a 1:2 dilution of the original serum.

## RESULTS

#### Identification of Polygalacturonase cDNAs

[0077] Twelve putative polygalacturonase clones were identified from the  $\lambda$ gt11 library by reaction with the antibody preparation described above. Using inserts purified from two of the clones as probes, Northern analysis demonstrated that one clone (C3) encoded mRNA expressed during tomato development in the manner and size expected for polygalacturonase mRNA.

[0078] To identify additional putative cDNA clones encoding polygalacturonase, phage DNA was prepared from the remaining 10 clones, digested with EcoRI and HindIII, and subjected to Southern blot hybridization analysis (Maniatis et al., *supra*) using clone C3 insert as a probe. An additional cDNA clone (P1) cross-hybridized to C3 and was further characterized to provide sequences for anti-sense expression. The identity of P1 as a polygalacturonase cDNA clone was confirmed by comparison of the amino acid sequence predicted from the DNA sequence to the actual polygalacturonase protein sequence. The clone encodes a portion of the polygalacturonase gene beginning approximately at the N-terminus of the mature polygalacturonase polypeptide and extending to the carboxy terminus including the 3' untranslated region.

#### Construction of the Anti-sense Polygalacturonase Binary Plasmid

[0079] Phage P1 DNA was digested with EcoRI and the cDNA insert was ligated in EcoRI-digested M13 Blue Scribe Minus (Stratagene) to yield pCGN1401.

[0080] pCGN1401 was digested with BamHI and EcoRI to provide a 219 bp fragment (Fig. 1) which includes 7 bases (GAATTCC) of the EcoRI linker, 2 bases of the polygalacturonase leader sequence (AT), the triplet encoding the N-terminal amino acid of the mature polygalacturonase protein (GGG) and 210 additional bases to the BamHI site. This fragment was inserted in the unique BamHI-EcoRI site of the mas5'-ocs3' cassette, pCGN46 (Comai et al. *Nature* (1983) 301:741-744). This resulted in insertion of the fragment in the anti-sense (minus orientation) to the mas promoter to yield pCGN1402.

[0081] pCGN1402 was then digested with the restriction enzyme XbaI and cloned into the unique SalI site of the binary plasmid pCGN783 containing a plant kanamycin resistance marker between the left and right borders. This results in pCGN1403. This plasmid in E. coli C2110 was conjugated into Agrobacterium tumefaciens containing a disarmed Ti plasmid capable of transferring the polygalacturonase anti-sense cassette and the kanamycin resistance cassette into the plant host genome.

[0082] The Agrobacterium system which is employed is A. tumefaciens PC2760 (G. Ooms et al. Plasmid (1982) et al. Nature (1983) 303:179-181; European Patent Application 84-200239.6, 2424183).

Construction of pCGN783

[0083] pCGN783 is a binary plasmid containing the left and right T-DNA borders of Agrobacterium tumefaciens octopine Ti-plasmid pTiA6 (Currier and Nester (1976) supra) the gentamycin resistance gene of pPH1 JI (Hirsch et al. Plasmid (1984) 12:139-141), the 35S promoter of cauliflower mosaic virus (CaMV) (Gardner et al. Nucleic Acid Res. (1981) 9:1871-1880); the kanamycin resistance gene of Tn5 (Jorgensen, Mol. Gen. (1979) 177:65); and the 3' region from transcript 7 of pTiA6 (Currier and Nester (1976), supra). The construction of pCGN783 is outlined in Fig. 2.

Construction of pCGN739 (Binary Vector)

[0084] To obtain the gentamicin resistance marker, the resistance gene was isolated from a 3.1kb EcoRI-PstI fragment of pPH1 JI (Hirsch et al. 1984, supra) and cloned into pUC9 (Vieira et al. Gene (1982) 19:259-268) yielding pCGN549.

[0085] The pCGN549 HindIII-BamHI fragment containing the gentamicin resistance gene replaced the HindIII-BglII fragment of pCGN587 (for construction, see infra) creating pCGN594.

[0086] The pCGN594 HindIII-BamHI region which contains an ocs-kanamycin-ocs fragment was replaced with the HindIII-BamHI polylinker region from pUC18 (Yanisch-Perron, 1985, supra) to make pCGN739.

Construction of 726c (1ATG-Kanamycin-3' region)

[0087] pCGN566 contains the EcoRI-HindIII linker of pUC18 (Yanisch-Perron, Ibid) inserted into the EcoRI-HindIII sites of pUC13-cm (K. Buckley, Ph.D. thesis, UC-San Diego, 1985). The HindIII-BglIII fragment of pNW31c-8, 29-1 (Thomashow et al. (1980) Cell 19:729) containing ORF1 and 2 (Barker et al. (1983), supra) was subcloned into the HindIII-BamHI sites of pCGN566 producing pCGN703.

[0088] The Sau3A fragment of pCGN703 containing the 3' region of transcript 7 from pTiA6 (corresponding to bases 2396-2920 of pTi15955 (Barker et al. (1983), supra) was subcloned into the BamHI site of pUC18 (Yanisch-Perron et al. (1985), supra) producing pCGN709.

[0089] The EcoRI-SmaI polylinker region of pCGN709 was replaced with the EcoRI-SmaI fragment from pCGN587 (for production see infra) which contains the kanamycin resistance gene (APH3'II) producing pCGN726.

[0090] The EcoRI-SalI fragment of pCGN726 plus the BglIII-EcoRI fragment of pCGN734 are inserted into the BamHI-SalI sites of pUC8-pUC13-cm (chloramphenical resistant, K. Buckley, PhD. Thesis, UC-San Diego, 1985) producing pCGN738. To construct pCGN734, the HindIII-SphI fragment of pTiA6 corresponding to bases 3390-3241 (Barker et al. (1983), supra) was cloned into the HindIII-SphI site of M13mp19 (Norrander et al. (1983), supra). Using an oligonucleotide corresponding to bases 3287 to 3300, DNA synthesis was primed from this template. Following S1 nuclease treatment and HindIII digestion, the resulting fragment was cloned into the HindIII-SmaI site of pUC19 (Yanisch-Perron et al. (1985), supra). The resulting EcoRI-HindIII fragment corresponding to bases 3287-3390 (Barker et al. (1983), supra) was cloned with the EcoRI to HindIII fragment of pTiA6 (corresponding to bases 3390-4494) into the EcoRI site of pUC8 (Vieira and Messing (1982), supra) resulting in pCGN734. pCGN726c is derived from pCGN738 by deleting the 900bp EcoRI-EcoRI fragment.

Construction of pCGN766c (35s promoter - 3' region)

[0091] The HindIII-BamHI fragment of pCGN167 (for construction see infra) containing the CaMV-35S promoter, 1ATG-kanamycin gene and the BamHI fragment 19 of pTiA6 was cloned into the BamHI-HindIII sites of pUC19 (Norrander et al. (1983), supra; Yanisch-Perron et al. (1985), supra) creating pCGN976.

[0092] The 35S promoter and 3' region from transcript 7 was developed by inserting a 0.7kb HindIII-EcoRI fragment of pCGN976 (35S promoter) and the 0.5kb EcoRI-SalI fragment of pCGN709 (transcript 7:3', for construction, see infra) into the HindIII-SalI sites of pCGN566 creating pCGN766c.

Final Construction of pCGN783

[0093] The 0.7kb HindIII-EcoRI fragment of pCGN766c (CaMV-35S promoter) was ligated to the 1.5kb EcoRI-Sall fragment of pCGN726c (1-ATG-KAN-3' region) into the HindIII-Sall sites of pUC119 (J. Vieira, Rutgers University, N. J.) to produce pCGN778.

[0094] The 2.2kb region of pCGN778, HindIII-Sall fragment containing the CaMV 35S promoter (1-ATG-KAN-3' region) replaced the HindIII-Sall polylinker region of pCGN739 to produce pCGN783.

[0095] pCGN587 was prepared as follows: The HindIII-Smal fragment of Tn5 containing the entire structural gene for APH3'II (Jorgenson et al. Mol. Gen. (1979) 177:65), was cloned into pUC8 (Vieira and Messing, Gene (1982), 19: 259), converting the fragment into a HindIII-EcoRI fragment, since there is an EcoRI site immediately adjacent to the Smal site. The PstI-EcoRI fragment containing the 3'-portion of the APH3'II gene was then combined with an EcoRI-BamHI-Sall-PstI linker into the EcoRI site of pUC7 (pCGN546W). Since this construct does not confer kanamycin resistance, kanamycin resistance was obtained by inserting the BgIII-PstI fragment of the APH3'II gene into the BamHI-PstI site (pCGN546X). This procedure reassembles the APH3'II gene, so that EcoRI sites flank the gene. An ATG codon was upstream from and out of reading frame with the ATG initiation codon of APH3'II. The undesired ATG was avoided by inserting a Sau3A-PstI fragment from the 5'-end of APH3'II, which fragment lacks the superfluous ATG, into the BamHI-PstI site of pCGN546W to provide plasmid pCGN550. The EcoRI fragment of pCGN550 containing the APH3'II gene was then cloned into the EcoRI site of pUC8-pUC13 (K. Buckley (1985), *supra*) to give pCGN551.

[0096] Each of the EcoRI fragments containing the APH3'II gene was then cloned into the unique EcoRI site of pCGN451, which contains an octopine synthase cassette for expression, (as described in Example 1) to provide pCGN548 (2ATG) and pCGN552 (1ATG). The plasmid pCGN451 having the ocs 5' and the ocs 3' in the proper orientation was digested with EcoRI and the EcoRI fragment from pCGN551 containing the intact kanamycin resistance gene inserted into the EcoRI site to provide pCGN552 having the kanamycin resistance gene in the proper orientation.

[0097] This ocs/KAN gene was used to provide a selectable marker for the trans type binary vector pCGN587.

[0098] The 5' portion of the engineered octopine synthase promoter cassette consists of pTIA6 DNA from the Xhol at bp 15208-13644 (Barker et al. (1983), *supra*), which also contains the T-DNA boundary sequence (border) implicated in T-DNA transfer. In the plasmid pCGN587, the ocs/KAN gene from pCGN552 provides a selectable marker as well the right border. The left boundary region was first cloned in M13mp9 as a HindIII-Smal piece (pCGN502) (base pairs 602-2212) and recloned as a KpnI-EcoRI fragment in pCGN565 to provide pCGN580. pCGN565 is a cloning vector based on pUC8-Cm, but containing pUC18 linkers. pCGN580 was linearized with BamHI and used to replace the smaller BgIII fragment of pVCK102 (Knauf and Nester, Plasmid (1982) 8:45), creating pCGN585. By replacing the smaller Sall fragment of pCGN585 with the Xhol fragment from pCGN552 containing the ocs/KAN gene, pCGN587 was obtained.

[0099] To construct pCGN167, the AluI fragment of CaMV (bp 7144-7735) (Gardner et al. Nucl. Acids Res. (1981) 9:2871-2888) was obtained by digestion with AluI and cloned into the HincII site of M13mp7 (Vieira Gene (1982) 19: 259) to create C614. An EcoRI digest of C614 produced the EcoRI fragment from C614 containing the 35S promoter which was cloned into the EcoRI site of pUC8 (Vieira et al. Gene (1982) 19:259) to produce pCGN146.

[0100] To trim the promoter region, the BgIII site (bp 7670) was treated with BgIII and Bal31 and subsequently a BgIII linker was attached to the Bal31 treated DNA to produce pCGN147.

[0101] pCGN148a containing a promoter region, selectable marker (KAN with 2 ATG's) and 3' region was prepared by digesting pCGN528 (see below) with BgIII and inserting the BamHI-BgIII promoter fragment from pCGN147. This fragment was cloned into the BgIII site of pCGN528 so that the BgIII site was proximal to the kanamycin gene of pCGN528.

[0102] The shuttle vector used for this construct, pCGN528, was made as follows. pCGN525 was made by digesting a plasmid containing Tn5 which harbors a kanamycin gene (Jorgenson et al. Mol. Gen. (1979) 177:65) with HindIII-BamHI and inserting the HindIII-BamHI fragment containing the kanamycin gene into the HindIII-BamHI sites in the tetracycline gene of pACYC184 (Chang & Cohen J. Bacteriol. (1978) 134:1141-1156). pCGN526 was made by inserting the BamHI fragment 19 9f pTIA6 (Thomashow et al. Cell (1980) 19:729-739) into the BamHI site of pCGN525. pCGN528 was obtained by deleting the small Xhol fragment from pCGN526 by digesting with Xhol and religating.

[0103] pCGN149a was made by cloning the BamHI kanamycin gene fragment from pMB9KanXXI into the BamHI site of pCGN148a.

[0104] pMB9KanXXI is a pUC4K variant (Vieira & Messing, Gene (1982) 19:259:268) which has the Xhol site missing but contains a functional kanamycin gene from Tn903 to allow for efficient selection in *Agrobacterium*.

[0105] pCGN149a was digested with BgIII and SphI. This small BgIII-SphI fragment of pCGN149a was replaced with the BamHI-SphI fragment from MI (see below) isolated by digestion with BamHI and SphI. This produces pCGN167, a construct containing a full length CaMV promoter, 1ATG-kanamycin gene, 3' end and the bacterial Tn903-type kanamycin gene. MI is an EcoRI fragment from pCGN550 (see construction of pCGN587) and was cloned into the EcoRI cloning site of M13mp9 in such a way that the PstI site in the 1ATG-kanamycin gene was proximal to the polylinker

region of M13mp9.

[0106] It is evident from the above results that it is possible to modulate expression of a gene in the genome of a plant host by providing for transcription of a sequence complementary to the messenger RNA of a gene expressed in the host. In this manner, various processes can be modified or controlled, resulting in enhancement of production of particular products, changes in cellular differentiation and development, inhibition of formation of products, changes in phenotype, or the like. The use of the anti-sense control can provide for substantial inhibition or varying degrees of reduction of expression of a particular product. In this manner, cellular phenotypes can be modified without the production of extraneous proteins and with particular targeting to a specific gene.

[0107] Although the foregoing invention has been described in some detail by way of illustration and example for purposes of clarity of understanding, it will be obvious that certain changes and modifications may be practiced.

[0108] pCGN978xK12 was deposited at the A.T.C.C. on 25th March 1986 and given Accession No.67064 and pCGN1401 was deposited on 7th October 1986 at the A.T.C.C. and given Accession No. 67227.

15 **Claims**

**Claims for the following Contracting States : BE, CH, DE, FR, GB, GR, IT, LU, NL, SE**

20 1. A method for regulating the expression of a gene in a plant cell which comprises:

integrating into said plant cell genome a construct comprising a promoter functional in said plant cell, a dsDNA sequence having the transcribed strand complementary to RNA endogenous in said cell and a termination region functional in said cell;

25 growing said plant cell containing said integrated construct, whereby said complementary strand is transcribed and modulates the function of said endogenous RNA in said cell, provided:

(i) that the gene is not a plant parasite gene; and  
30 (ii) that said dsDNA sequence is not a polygalacturonase (PG) DNA sequence as found in the EcoRI insert of plasmid pCGN1401 (ATCC67227), or as obtainable by the use of said insert DNA as a hybridization probe.

2. A method according to claim 1, wherein said endogenous RNA is messenger RNA.

35 3. A method according to claim 2, wherein modulation of said function results in an altered phenotypic trait.

4. A method according to claim 2 or 3 wherein the transcribed strand includes at least 15 nt of the translated region of said messenger RNA.

40 5. A method according to claim 2 or 3 wherein the transcribed strand includes at least 15 nt of the 5' untranslated sequence of said messenger RNA.

6. A method according to claim 2 or 3 wherein the transcribed strand includes at least 15 nt of the 3' untranslated sequence of said messenger RNA.

45 7. A method according to any one of claims 2 to 6, wherein modulation of said function results in an altered phenotypic trait.

8. A plant cell prepared according to the method of any one of the preceding claims.

50 9. A plant cell according to claim 8 wherein said plant cell is a monocot plant cell.

10. A plant cell according to claim 8 wherein said plant cell is a dicot plant cell.

55 11. A plant cell according to claim 8 wherein said plant cell is a gymnosperm plant cell.

12. A DNA construct comprising a transcriptional initiation region functional in a plant cell, a dsDNA sequence having as the transcribed strand a sequence complementary to an RNA sequence endogenous to a plant cell, and a

transcriptional termination region, provided:

5 (i) that said RNA sequence is not a plant parasite RNA sequence;  
(ii) is not a zein sequence; and  
(iii) is not a polygalacturonase (PG) DNA sequence as found in the EcoRI insert of plasmid pCGN1401 (ATCC67227), or as obtainable by the use of said insert DNA as a hybridization probe.

13. A DNA construct according to claim 12 including a sequence coding for a marker capable of selection in a plant cell.  
10 14. A plasmid comprising a replication system functional in a prokaryotic host and a DNA construct according to any one of claims 12 or 13.  
15 15. A plasmid comprising a replication system functional in Agrobacterium and a DNA construct according to any one of claims 12 to 14 containing at least one T-DNA border.  
16 16. A plant derived from and comprising a cell according to any one of claims 8 to 11 or a plant comprising a cell which has been transformed with a DNA construct or plasmid according to any one of claims 12 to 15.

20 **Claims for the following Contracting States : AT, ES**

1. A method for regulating the expression of a gene in a plant cell which comprises:  
25 Integrating into said plant cell genome a construct comprising a promoter functional in said plant cell, a dsDNA sequence having the transcribed strand complementary to RNA endogenous in said cell and a termination region functional in said cell;  
growing said plant cell containing said integrated construct, whereby said complementary strand is transcribed and modulates the function of said endogenous RNA in said cell, provided:  
30 (i) that the gene is not a plant parasite gene; and  
(ii) that said dsDNA sequence is not a polygalacturonase (PG) DNA sequence as found in the EcoRI Insert of plasmid pCGN1401 (ATCC67227), or as obtainable by the use of said insert DNA as a hybridization probe.  
35 2. A method according to claim 1, wherein said endogenous RNA is messenger RNA.  
3. A method according to claim 2, wherein modulation of said function results in an altered phenotypic trait.  
40 4. A method according to claim 2 or 3 wherein the transcribed strand includes at least 15 nt of the translated region of said messenger RNA.  
5. A method according to claim 2 or 3 wherein the transcribed strand includes at least 15 nt of the 5' untranslated sequence of said messenger RNA.  
45 6. A method according to claim 2 or 3 wherein the transcribed strand includes at least 15 nt of the 3' untranslated sequence of said messenger RNA.  
7. A method according to any one of claims 2 to 6, wherein modulation of said function results in an altered phenotypic trait.  
50

**Patentansprüche**

55 **Patentansprüche für folgende Vertragsstaaten : BE, CH, DE, FR, GB, CR, IT, LU, NL, SE**

1. Verfahren zum Steuern der Expression eines Gens in einer Pflanzenzelle, Folgendes umfassend:

das Integrieren eines Konstrukts, das einen in der Pflanzenzelle funktionellen Promotor, eine dsDNA-Sequenz, deren transkribierter Strang zu in der Zelle endogener RNA komplementär ist, sowie eine in der Zelle funktionelle Terminationsregion umfasst, in das Pflanzenzellengenom;

5 das Züchten der Pflanzenzelle, die das Integrierte Konstrukt enthält, wodurch der komplementäre Strang transkribiert wird und die Funktion der endogenen RNA in der Zelle moduliert, mit der Maßgabe:

(I) dass das Gen kein Pflanzenparasiten-Gen ist; und  
(II) dass die dsDNA-Sequenz keine Polygalacturonase- (PG-) DNA-Sequenz ist, wie sie im EcoRI-Insert von Plasmid pCGN1401 (ATCC 67227) vorkommt oder wie sie unter Verwendung der Insert-DNA als Hybridisierungssonde erhältlich ist.

10

2. Verfahren nach Anspruch 1, worin die endogene RNA Messenger-RNA ist.

3. Verfahren nach Anspruch 2, worin die Modulation der Funktion zu einem veränderten phenotypischen Merkmal führt.

15

4. Verfahren nach Anspruch 2 oder 3, worin der transkribierte Strang zumindest 15 nt der translatierten Region der Messenger-RNA umfasst.

20

5. Verfahren nach Anspruch 2 oder 3, worin der transkribierte Strang zumindest 15 nt der untranslatierten 5'-Sequenz der Messenger-RNA umfasst.

25

6. Verfahren nach Anspruch 2 oder 3, worin der transkribierte Strang zumindest 15 nt der untranslatierten 3'-Sequenz der Messenger-RNA umfasst.

7. Verfahren nach einem der Ansprüche 2 bis 6, worin die Modulation der Funktion zu einem geänderten phenotypischen Merkmal führt.

30

8. Nach dem Verfahren nach einem der vorangegangenen Ansprüche erzeugte Pflanzenzelle.

9. Pflanzenzelle nach Anspruch 8, worin die Pflanzenzelle die Zelle einer einkeimblättrigen Pflanze ist.

10. Pflanzenzelle nach Anspruch 8, worin die Pflanzenzelle die Zelle einer zweikeimblättrigen Pflanze ist.

35

11. Pflanzenzelle nach Anspruch 8, worin die Pflanzenzelle die Zelle einer nacktsamigen Pflanze ist.

12. DNA-Konstrukt, das eine in einer Pflanzenzelle funktionelle Transkriptionsinitiationsregion, eine dsDNA-Sequenz, die als transkribierten Strang eine zu einer in einer Pflanzenzelle endogenen RNA-Sequenz komplementäre Sequenz aufweist, sowie eine Transkriptionsterminationsregion umfasst, mit der Maßgabe dass die RNA-Sequenz:

40

(I) keine Pflanzenparasiten-RNA-Sequenz ist;  
(II) keine Zeinsequenz ist; und  
(III) keine Polygalacturonase- (PG-) DNA-Sequenz ist, wie sie im EcoRI-Insert von Plasmid pCGN1401 (ATCC 67227) vorkommt oder wie sie unter Verwendung der Insert-DNA als Hybridisierungssonde erhältlich ist.

45

13. DNA-Konstrukt nach Anspruch 12, die eine Sequenz umfasst, die für einen zur Selektion in einer Pflanzenzelle fähigen Marker kodiert.

14. Plasmid, das ein in einem prokaryotischen Wirt funktionelles Replikationssystem und ein DNA-Konstrukt nach einem der Ansprüche 12 oder 13 umfasst.

50

15. Plasmid, das ein in einem Agrobacterium funktionelles Replikationssystem und ein DNA-Konstrukt nach einem der Ansprüche 12 bis 14 umfasst, das zumindest einen T-DNA-Rand umfasst.

55

16. Pflanze, die von einer Zelle nach einem der Ansprüche 8 bis 11 abgeleitet ist und diese umfasst, oder eine Pflanze, die eine Zelle umfasst, die mit einem DNA-Konstrukt oder Plasmid nach einem der Ansprüche 12 bis 15 transformiert wurde.

**Patentansprüche für folgende Vertragsstaaten : AT, ES**

**1. Verfahren zum Steuern der Expression eines Gens in einer Pflanzenzelle, Folgendes umfassend:**

5 das Integrieren eines Konstrukts, das einen in der Pflanzenzelle funktionellen Promotor, eine dsDNA-Sequenz, deren transkribierter Strang zu in der Zelle endogener RNA komplementär ist, sowie eine in der Zelle funktionelle Terminationsregion umfasst, in das Pflanzenzellengenom;  
das Züchten der Pflanzenzelle, die das integrierte Konstrukt enthält, wodurch der komplementäre Strang transkribiert wird und die Funktion der endogenen RNA in der Zelle moduliert, mit der Maßgabe:  
10 (I) dass das Gen kein Pflanzenparasiten-Gen ist; und  
(II) dass die dsDNA-Sequenz keine Polygalacturonase- (PG-) DNA-Sequenz ist, wie sie im EcoRI-Insert von Plasmid pCGN1401 (ATCC 67227) vorkommt oder wie sie unter Verwendung der Insert-DNA als Hybridisierungssonde erhältlich ist.  
15 2. Verfahren nach Anspruch 1, worin die endogene RNA Messenger-RNA ist.  
3. Verfahren nach Anspruch 2, worin die Modulation der Funktion zu einem veränderten phenotypischen Merkmal führt.  
20 4. Verfahren nach Anspruch 2 oder 3, worin der transkribierte Strang zumindest 15 nt der translatierten Region der Messenger-RNA umfasst.  
5. Verfahren nach Anspruch 2 oder 3, worin der transkribierte Strang zumindest 15 nt der untranslatierten 5'-Sequenz 25 der Messenger-RNA umfasst.  
6. Verfahren nach Anspruch 2 oder 3, worin der transkribierte Strang zumindest 15 nt der untranslatierten 3'-Sequenz der Messenger-RNA umfasst.  
30 7. Verfahren nach einem der Ansprüche 2 bis 6, worin die Modulation der Funktion zu einem geänderten phenotypischen Merkmal führt.

**Revendications**

35

**Revendications pour les Etats contractants suivants : BE, CH, DE, FR, GB, GR, IT, LU, NL, SE**

**1. Méthode pour réguler l'expression d'un gène dans une cellule de plante qui comprend:**

40 l'intégration dans ledit génome de la cellule de plante d'une construction comprenant un promoteur fonctionnel dans ladite cellule de plante, une séquence d'ADNdb ayant le brin complémentaire transcrit à l'ARN endogène dans ladite cellule et une région de terminaison fonctionnelle dans ladite cellule; et  
la croissance de ladite cellule de plante contenant ladite construction intégrée, ainsi ledit brin complémentaire 45 est transcrit et module la fonction dudit ARN endogène dans ladite cellule, à condition que:  
(i) le gène ne soit pas un gène parasite de plante; et  
(ii) ladite séquence d'ADNdb ne soit pas une séquence d'ADN de polygalacturonase (PG) telle que trouvée dans l'insert de EcoRI du plasmide pCGN1401 (ATCC67227), où comme on peut l'obtenir par l'utilisation dudit ADN d'insert en tant que sonde d'hybridation.  
50 2. Méthode selon la revendication 1, où ledit ARN endogène est l'ARN messager.  
3. Méthode selon la revendication 2, où la modulation de ladite fonction a pour résultat un trait phénotypique modifié.  
55 4. Méthode selon la revendication 2 ou 3 où le brin transcrit comprend au moins 15 nt de la région traduite dudit ARN messager.

5. Méthode selon la revendication 2 ou 3 où le brin transcrit comprend au moins 15 nt de la séquence non traduite côté 5' dudit ARN messager.
6. Méthode selon la revendication 2 ou 3 où le brin transcrit comprend au moins 15 nt de la séquence non traduite côté 3' dudit ARN messager.
7. Méthode selon l'une quelconque des revendications 2 à 6, où la modulation de ladite fonction a pour résultat un trait phénotypique modifié.
10. 8. Cellule de plante préparée selon la méthode de l'une quelconque des revendications précédentes.
9. Cellule de plante selon la revendication 8 où ladite cellule de plante est une cellule de plante monocotylédon.
10. Cellule de plante selon la revendication 8 où ladite cellule de plante est une cellule de plante dicotylédon.
15. 11. Cellule de plante selon la revendication 8 où ladite cellule de plante est une cellule de plante gymnosperme.
12. Construction d'ADN comprenant une région d'initiation de transcription fonctionnelle dans une cellule de plante, une séquence d'ADNdb ayant comme brin transcrit une séquence complémentaire d'une séquence d'ARN endogène à une cellule de plante, et une région de terminaison de transcription, à condition que:
  - (i) ladite séquence d'ARN ne soit pas une séquence d'ARN d'un parasite de plante;
  - (ii) ne soit pas une séquence zein; et
  - (iii) ne soit pas une séquence d'ADN de polygalacturonase (PG) telle que trouvée dans l'Insert de EcoRI du plasmide pCGN1401 (ATCC67227), ou telle qu'on peut l'obtenir par l'utilisation dudit ADN d'insert en tant que sonde d'hybridation.
30. 13. Construction d'ADN selon la revendication 12 comprenant une séquence codant pour un marqueur capable de sélection dans une cellule de plante.
14. Plasmide comprenant un système de réplication fonctionnel chez un hôte procaryote et une construction d'ADN selon l'une quelconque des revendications 12 ou 13.
35. 15. Plasmide comprenant un système de réplication fonctionnel dans Agrobacterium et une construction d'ADN selon l'une quelconque des revendications 12 à 14 contenant au moins une bordure d'ADN-T.
16. Plante dérivée de et comprenant une cellule selon l'une quelconque des revendications 8 à 11 ou une plante comprenant une cellule qui a été transformée avec une construction d'ADN ou un plasmide selon l'une quelconque des revendications 12 à 15.

40

**Revendications pour les Etats contractants suivants : AT, ES**

1. Méthode pour réguler l'expression d'un gène dans une cellule de plante qui comprend:
  45. l'intégration dans ledit génome de la cellule de plante d'une construction comprenant un promoteur fonctionnel dans ladite cellule de plante, une séquence d'ADNdb ayant le brin complémentaire transcrit à l'ARN endogène dans ladite cellule et une région de terminaison fonctionnelle dans ladite cellule; et
  50. la croissance de ladite cellule de plante contenant ladite construction intégrée, ainsi ledit brin complémentaire est transcrit et module la fonction dudit ARN endogène dans ladite cellule, à condition que:
    - (i) le gène ne soit pas un gène parasite de plante; et
    - (ii) ladite séquence d'ADNdb ne soit pas une séquence d'ADN de polygalacturonase (PG) telle que trouvée dans l'Insert de EcoRI du plasmide pCGN1401 (ATCC67227), où comme on peut l'obtenir par l'utilisation dudit ADN d'insert en tant que sonde d'hybridation.

2. Méthode selon la revendication 1, où ledit ARN endogène est l'ARN messager.
3. Méthode selon la revendication 2, où la modulation de ladite fonction a pour résultat un trait phénotypique modifié.
5. 4. Méthode selon la revendication 2 ou 3 où le brin transcrit comprend au moins 15 nt de la région traduite dudit ARN messager.
5. 5. Méthode selon la revendication 2 ou 3 où le brin transcrit comprend au moins 15 nt de la séquence non traduite côté 5' dudit ARN messager.
10. 6. Méthode selon la revendication 2 ou 3 où le brin transcrit comprend au moins 15 nt de la séquence non traduite côté 3' dudit ARN messager.
15. 7. Méthode selon l'une quelconque des revendications 2 à 6, où la modulation de ladite fonction a pour résultat un trait phénotypique modifié.

20

25

30

35

40

45

50

55

StyI  
 SecI  
 NcoI  
 EcoRI - NlaIII  
 DsAI  
 |  
 |  
 1 GAATTCCATGGGATTAAAGTGATTAATGTACTTAGCTTGGAGCTAAGGGTGATGGAAAAACATATGAT 69  
GlyIleLysValIleAsnValLeuSerPheGlyAlaLysGlyAspGlyLysThrTyrAsp  
 7 30 36 44 62  
 2 11 32 45 64  
 7  
 7  
 7

SspI NlaIII Tth111II MaeI XbaI  
 | | | | Nsp(7524) I  
 | | | | NlaIII  
 70 AATATTGCATTCAGCAAGCATGGAATGAAGCATGTTCATCTAGAACACCTGTTCAATTGTTGGTTCCCT 138  
 AsnIleAlaPheGluGlnAlaTrpAsnGluAlaCysSerSerArgThrProValGlnPheValValPro  
 73 93 102 111 135  
 105  
 105  
 110

MboII HphI HgiEII Tth111II Avall MboI XbaII  
 | | | | | | NlaIII  
 | | | | | | MboII  
 139 AAAACAAGAATTATCTTCTCAAGCAAATCACCTTCAGGTCCATGCAGATCTTCTATTCAGTAAG 207  
 LysAsnLysAsnTyrLeuLeuLysGlnIleThrPheSerGlyProCysArgSerSerIleSerValLys  
 146 160 169 179 188  
 179 190  
 176 188  
 183  
 186  
 188

XbaII NlaIV DpnI  
 MboI BlnI BamHI  
 208 ATTTTTGGATCC IlePheGlySer  
 210 215  
 215  
 217  
 217  
 215

FIG.1

FIG. 1




FIG. 2

Construction of PCGN 783